[Federal Register Volume 72, Number 165 (Monday, August 27, 2007)]
[Notices]
[Page 49019]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-16862]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Prior to issuing a registration under 21 U.S.C. 952(a) (2) (B), and 
in accordance with 21 CFR 1301.34 (a), this is notice that on July 20, 
2007, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, TX 
78664, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as an importer of the basic 
classes of controlled substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
Fenethylline (1503)........................  I
Gamma hydroxybutyric acid (2010)...........  I
Ibogaine (7260)............................  I
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
Alpha-methyltryptamine (7432)..............  I
Diethyltryptamine (7434)...................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
Phencyclidine (7471).......................  I
N-Benzylpiperazine (7493)..................  I
Etorphine (except HCI)(9056)...............  I
Heroin (9200)..............................  I
Morphine-N-oxide (9307)....................  I
Normorphine (9313).........................  I
Pholcodine (9314)..........................  I
Dextromoramide (9613)......................  I
Dipipanone (9622)..........................  I
Trimeperidine (9646).......................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Ethylmorphine (9190).......................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Poppy Straw Concentrate (9670).............  II
------------------------------------------------------------------------

    The company plans to import small quantities of the listed 
controlled substances for the manufacture of analytical reference 
standards.
    Any bulk manufacturers who are presently, or are applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
Washington, DC. 20537; or any being sent via express mail should be 
sent to Drug Enforcement Administration, Office of Diversion Control, 
Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, 
Alexandria, Virginia 22301; and must be filed no later than September 
26, 2007.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substances in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), 
(c), (d), (e), and (f) are satisfied.

    Dated: August 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-16862 Filed 8-24-07; 8:45 am]
BILLING CODE 4410-09-P